CHMA
Chiasma, Inc. [CHMA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CHMA Stock Summary
In the News
CHMA Financial details
Company Rating
-
Market Cap
0
Income
-89.94M
Revenue
3.03M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
84
Optionable
No
Shortable
Yes
Earnings
09 Aug 2021
P/E
-2.63
Forward P/E
-
PEG
-0.51
P/S
-
P/B
2.14
P/C
-
P/FCF
-
Quick Ratio
8.13
Current Ratio
9.17
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.61
EPS next Y
-
EPS next Q
-
EPS this Y
34.91%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
99.59%
EPS Q/Q
53.13%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-42%
ROE
-84%
ROC
-0.44%
Gross Margin
94%
Oper. Margin
-6388%
Profit Margin
-6761%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.76-4.1
52W High
-6%
52W Low
+25.33%
RSI
-
Rel Volume
8.23
Avg Volume
996.38K
Volume
8.2M
Perf Week
0%
Perf Month
0%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
1.25659
-
-
Volatility
0%, 0%
Prev Close
0%
Price
3.76
Change
-
Company Profile
- Volume Average 996.38K
- Employee 84
- CEO Mr. Raj Kannan
- Headquarters Needham,MASSACHUSETTS,US
- IPO Date 2015-07-16
-
Website
http://www.chiasma.com 
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
